1 BA.1 and **BA.2** sub-lineages of Omicron variant have comparable replication

2 kinetics and susceptibility to neutralization by antibodies

- 3 **Running title:** Replication kinetics of SARS-CoV-2 variants
- 4 Janmejay Singh^{1*}, Aleksha Panwar^{1*}, Anbalagan Anantharaj^{1*}, Chitra Rani¹, Monika
- 5 Bhardwaj¹, Parveen Kumar¹, Kamal Pargai¹, Partha Chattopadhyay^{2,3}, Priti Devi^{2,3},
- 6 Ranjeet Maurya^{2,3}, Pallavi Mishra², Anil Kumar Pandey⁴, Rajesh Pandey² and
- 7 Guruprasad R. Medigeshi^{1#}
- 8 1. Bioassay Laboratory and Clinical and Cellular Virology Laboratory, Translational
- 9 Health Science and Technology Institute, Faridabad, Haryana. INDIA.
- 10 2: INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) laboratory, CSIR-Institute
- 11 of Genomics and Integrative Biology, Delhi, INDIA.
- 12 3: Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India.
- 13 4: Employees State Insurance Corporation Medical College and Hospital, Faridabad,
- 14 Haryana, INDIA.
- 15 * These authors contributed equally
- 16 **# Corresponding author:**
- 17 Guruprasad R. Medigeshi, PhD
- 18 Translational Health Science and Technology Institute,
- 19 NCR-Biotech Science Cluster,
- 20 P.O. Box # 4, Faridabad-Gurugram Highway,
- Faridabad 121001. INDIA.
- 22 Tel: +91-0129-2876311.
- 23 Email: gmedigeshi@thsti.res.in

24 ABSTRACT

The Omicron variant of SARS-CoV-2 is capable of infecting unvaccinated, vaccinated 25 and previously-infected individuals due to its ability to evade neutralization by 26 27 antibodies. With three sub-lineages of Omicron emerging in the last four months, there is inadequate information on the quantitative antibody response generated upon natural 28 infection with Omicron variant and whether these antibodies offer cross-protection 29 against other sub-lineages of Omicron variant. In this study, we characterized the 30 growth kinetics of Kappa, Delta and Omicron variants of SARS-CoV-2 in Calu-3 cells. 31 Relatively higher amounts infectious virus titers, cytopathic effect and disruption of 32 epithelial barrier functions was observed with Delta variant whereas infection with 33 Omicron variant led to a more robust induction of interferon pathway, lower level of virus 34 replication and mild effect on epithelial barrier. The replication kinetics of BA.1 and BA.2 35 sub-lineages of the Omicron variant were comparable in cell culture and natural 36 37 Omicron infection in a subset of individuals led to a significant increase in binding and neutralizing antibodies to both BA.1 and BA.2 sub-lineages but these levels were lower 38 than that produced against the Delta variant. Finally, we show that Cu²⁺, Zn²⁺ and Fe²⁺ 39 salts inhibited in vitro RdRp activity but only Cu²⁺ and Fe²⁺ inhibited both the Delta and 40 Omicron variants in cell culture. Thus, our results suggest that high levels of interferons 41 induced upon infection with Omicron variant may counter virus replication and spread. 42 Waning neutralizing antibody titers rendered subjects susceptible to infection by 43 Omicron variant and natural Omicron infection elicits neutralizing antibodies that can 44 cross-react with other sub-lineages of Omicron and other variants of concern. 45

46 **KEYWORDS:** SARS-CoV-2; COVID-19; Delta variant; Omicron; RdRp; Copper; Iron

47 **INTRODUCTION**

Close to 17 million cases of COVID-19 was reported from India during the second wave 48 of SARS-CoV-2 from March 2021 to June 2021 overwhelming the public health 49 50 infrastructure resulting in close to 40% of the >500,000 deaths that has occurred in this 51 pandemic. The surge was due to novel SARS-CoV-2 variant from the lineage B.1.617.2 52 (Delta variant) which was shown to be more virulent with shorter incubation periods and 53 ability to cause severe disease(1-4). Many reports have shown that the neutralizing 54 antibodies from prior infection or that elicited by some of the licensed COVID-19 55 vaccines show a decrease in the efficiency to neutralize the Delta variant thereby 56 compromising vaccine efficacy against this variant (5-7). Delta variant was the major 57 circulating SARS-CoV-2 variant until the emergence of B.1.1.529 (Omicron) variant in 58 November 2021 which has now replaced the Delta variant in most of the countries. The ongoing third wave of SARS-CoV-2 infections, which is on the decline and attributed to 59 60 the Omicron variant of SARS-CoV-2, has resulted in milder symptoms and lower hospitalizations. In addition to the less virulent Omicron variant, increased vaccination 61 62 coverage and hybrid immunity may have contributed to reduced impact of third wave in 63 India. Three sub-lineages of Omicron (BA.1, BA.2 and BA.3) have emerged and are 64 currently circulating in India and other parts of the world(8). The success of Omicron variant and its sub-lineages in driving the current phase of the pandemic has been 65 attributed to a large number of mutations leading to escape from neutralizing antibodies 66 generated by prior infection or vaccination(9-12). Recent reports suggest that the 67 68 antibody response between the sub-lineages may not be significantly different and

exposure to one of the sub-lineages offers cross-protection against other members of
Omicron sub-lineage and also against past variants(<u>13</u>, <u>14</u>).

71

In addition to evading humoral immunity, data from animal models suggest that the 72 success of SARS-CoV-2 variants of concern (VoCs) in driving new waves of infection 73 74 can be attributed to multiple factors such as increased virulence, enhanced transmission, altered pathogenicity and replication fitness (15-20). Therefore, efforts to 75 characterize and understand the replication kinetics of circulating VoCs would provide 76 77 information on virulence mechanisms, immune evasion properties and augment our ability to develop therapeutic strategies. In this study, we compared the replication 78 79 kinetics of some of the SARS-CoV-2 VoCs namely, the Kappa and Delta variants and 80 BA.1 and BA.2 sub-lineages of Omicron variant in human lung epithelial adenocarcinoma (Calu-3) cells grown on transwells and also in air-liquid interface 81 82 models. We monitored the interferon response and its downstream effectors in infected cells and tested the effect of divalent cations on virus infection and RNA-dependent 83 84 RNA polymerase (RdRp) activity. We show that both binding and neutralizing antibodies 85 wane by >50% in six months in a cohort of participants with hybrid immunity. Natural 86 exposure to the Omicron variant led to a significant increase in binding and neutralizing 87 antibodies to BA.1 and BA.2 sub-lineages of Omicron. The levels of neutralizing 88 antibodies were higher against the Delta variant as compared to the Omicron sub-89 lineages. These data suggest that Omicron infection elicits neutralizing antibodies that can cross-react with other sub-lineages of Omicron and other VoCs in people with 90 hybrid immunity. Our results provide clues to the relative replication fitness of these 91

VoCs and their ability to induce interferon responses and susceptibility to divalent
 cations and may help to develop novel strategies to counter viral replication.

94

95 **RESULTS**

96 Peak COVID-19 positivity in second wave coincides with high viral load

A total of 117,434 NP/OP swab samples were tested for COVID-19 by RT-PCR at the 97 bioassay laboratory of the institute from April 2020 to July 2021. Peak positivity in the 98 year 2020 was observed in the months of June-July with 15% positivity during these 99 100 months (Supplementary Fig. S1A(i)). Previous reports have identified B.6 lineage as 101 one of the predominant lineages during this period circulating in India (21, 22). We have 102 isolated few clinical isolates from B.6 lineage as reported earlier and plague-purified one of the isolates which was used in this study as a representative of ancestral virus isolate 103 104 (23). The number of positive cases was around 10% of the total samples tested until 105 November 2020 and dropped drastically to around 0.1% of the total tested samples in 106 the month of February 2021 (Supplementary Fig. S1A(ii)). Although only 8 of the 8012 107 tested samples were RT-PCR positive in February 2021, 4 of these 8 samples had RT-108 PCR cycle threshold (Ct) values <20 and 2 with Ct values between 20-25. RT-PCR 109 positivity jumped to 1.1% (85 out of 7558) in March with over 50% of the positive 110 samples having Ct values of <25 clearly indicating a large number of infections with a 111 high viral load during February and March 2021 (Supplementary Fig. S1B). The 112 following months of April and May saw a sudden spike in the peak positivity rate which increased to 27.7% and 24.5% which is now termed as the "second wave" and the 113 114 SARS-CoV-2 variants from B.1.617.1/2 (Kappa/Delta) lineages have been attributed to

this sudden spike which overwhelmed the healthcare infrastructure leading to large scale mortality (24). 40% of the NP/OP samples tested in April 2021 had Ct values of less than 25 which reduced to 28% of the total samples in May indicating a high viral burden in patients during this period resulting in increased transmission of the virus among the contacts.

120

121 Disruption of cellular junctions by SARS-CoV-2 Delta and Kappa variants

We were able to isolate the B.1.617.1 (Kappa) and B.1.617.2 (Delta) variants from 122 123 clinical samples and got the virus stocks verified by whole genome sequencing. We measured the growth kinetics of these two variants in comparison with the B.6 lineage 124 125 virus. Calu-3 cells were infected with 0.01 MOI of SARS-CoV-2 from lineages B.6, 126 B.1.617.1 and B.1.617.2 respectively. We estimated viral titers in the supernatants at 24 and 48 h pi by plaque assay. Total RNA was isolated from cells at each time point for 127 128 measuring copy numbers of N gene by quantitative RT-PCR. We observed a significantly higher viral titers with B.1.617.2 variant relative to B.6 lineage virus at 24 h 129 pi. The virus titers at 48 h pi was reduced in both the Kappa and the Delta variant 130 131 samples most probably due to the increased cytopathic effect at this time point (Fig. 1A). However, no difference in N gene RNA copy numbers were detected between the 132 133 three isolates by RT-PCR at either of the time-points (Fig. 1B). As SARS-CoV-2 was 134 shown to disrupt tight junctions in Calu-3 and human airway epithelial cells (23, 25), we further assessed the effect of infection of B.6 and B.1.617.1 and B.1.617.2 variants on 135 cellular junctions of polarized Calu-3 cells. Cells were grown on transwell culture inserts 136 137 for 21 days to allow for polarization into apical and basolateral surface and formation of

138 permeability barrier as measured by the trans-epithelial electrical resistance (TEER). Polarized Calu-3 cells were infected with 0.3 MOI of each of the three virus isolates and 139 the TEER was monitored for 48 hours. Cells that were either mock-infected or infected 140 141 with B.6 lineage virus showed no significant change in TEER up to 48 h (Fig. 1C). Epithelial barrier function was disrupted by 48 h in cells infected with either the Kappa 142 (B.1.617.1) or the Delta (B.1.617.2) variants. However, a significant decline in the TEER 143 values was observed for the Delta variant (Fig.1C). Surprisingly, the virus titers in either 144 the apical or basolateral chambers were not significantly different between the three 145 isolates (Fig. 1D) at 48 h pi suggesting that the increasing cytopathogenicity by the 146 Delta variant may be responsible for significantly higher disruption of lung epithelial 147 barrier functions. These findings were further corroborated by confocal microscopy 148 where transwell culture inserts were fixed at 48 h pi and stained with antibodies against 149 SARS-CoV-2 nucleocapsid (N) protein, occludin (marker for tight junction) and β -150 151 catenin (marker for adherens junction) (Fig. 2). The staining pattern of both occludin and 152 β-catenin was comparable between mock- and B.6-infected cells. However, the same was perturbed in both the Kappa and the Delta variant infected cells and disruption of 153 occludin staining appeared to be more drastic in cells infected with the Delta variant 154 155 compared to the Kappa variant (Fig. 2). Our results suggest that the Delta variant infection has relatively more deleterious effects on epithelial cell functions most 156 probably due to increased fusogenic functions leading to syncytia formation and cell 157 death(19). 158

159

160 Infection with Omicron variant generates lower levels of infectious virus

Delta variant was reported to have higher transmissibility and pathogenicity in humans 161 and animal models(19, 26-28) whereas Omicron variant showed attenuated growth(17, 162 29). We performed growth curve analysis of SARS-CoV-2 viruses from the lineages B.6 163 (isolate from 2020), B.1.617.2 (Delta) and B.1.1.529 (Omicron) in Calu-3 cells by 164 165 infecting cells with 0.3 MOI and estimating viral genome equivalents (N gene) by gRT-166 PCR from infected cells and virus titers from culture supernatants by plaque assays at 167 indicated time-points (Fig. 3). We found that viral RNA replication peaked by 24 h pi for both the B.6 and the Delta variants and both these isolates had comparable viral N-168 gene levels by gRT-PCR at all the time points. However, the same for Omicron variant 169 170 was about 70% lower as compared to the other two lineages at all the time-points (Fig. 171 3A). Similarly, viral titers in the supernatant increased from 12 h pi to 24 h pi and the levels were maintained at 36 h pi in the case of B.6 lineage virus. However, consistent 172 with the sub-genomic N RNA levels, the viral titers for the Omicron variant was 173 174 significantly lower compared to both B.6 and the Delta variant at all the time points (Fig. 175 3B) which is in agreement with recent reports(30, 31). These observations were further 176 corroborated by western blot analysis performed with cell lysates prepared from infected 177 cells collected in lysis buffer at 12 and 24 h pi where the N protein was consistently 178 lower at both 12 and 24 h pi in cells infected with Omicron as compared to B.6 and Delta infection (Fig. 3C). To further verify whether the lower titers observed in the 179 Omicron infection is due to compromised viral entry, we performed viral entry 180 181 experiments by infecting cells with 5 MOI for one hour and estimated the amount of internalized RNA by qRT-PCR. We found that, contrary to reduced viral titers and viral 182 RNA levels in Omicron infection, the intracellular viral RNA levels were higher as 183

compared to B.6 and the Delta variant suggesting that the reduced viral titers and viral
 RNA levels is not due to compromised viral entry into these cells (Fig. 3D).

186

Interferon-dependent responses and reduced barrier disruption by Omicron variant

Innate immune responses mediated by interferons act as the first line of defence 189 against viral infections and SARS-CoV-2 was found to be less capable of evading the 190 interferon response compared to SARS-CoV-1(32) (33). Additionally, interferon induction 191 192 coincided with viral clearance in young adults with mild SARS-CoV-2 infection suggesting a crucial role for antiviral response in resolving infection(34). We tested the 193 194 induction of interferon-dependent antiviral response genes in cells infected with B.6, Delta and Omicron lineages. Total RNA isolated from Calu-3 cells after indicated time-195 points post-infection were used to estimate the transcript levels of interferon pathway 196 197 genes by RT-qPCR (Fig. 4). We found that infection with Omicron variant led to 198 significantly higher induction of interferon- β (Fig. 4A) and the epithelial cell specific interferon- $\lambda 1$ (Fig. 4B) and the downstream effectors of interferon pathway namely, 199 interferon-stimulated gene 15 (ISG15) (Fig. 4C) and 2'-5'-oligoadenylate synthetase 1 200 201 (OAS1) (Fig. 4D) at all the time-points tested suggesting that SARS-CoV-2 ancestral 202 virus (B.6) and both the variants induce innate immune responses and lower levels of 203 titers observed in the Omicron infected cells is due to robust induction of interferon pathway which is in agreement with previous reports(35). To further confirm that the 204 lower levels of replication and infection by Omicron variant translates to compromised 205 ability to disrupt the epithelial barrier functions, we compared the effect of Delta and 206

medRxiv preprint doi: https://doi.org/10.1101/2022.01.28.22269990; this version posted June 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

207 Omicron variant infection in an air-liquid culture model using Calu-3 cells. Cells were cultured on transwells at the air-liquid interface and infected with respective virus strains 208 at 0.3 MOI. Trans-epithelial electrical resistance was monitored for 36 h (Fig. 5A). We 209 210 observed a gradual insignificant decline in the TEER values after 12 h pi in cells infected with the Omicron variant and, by 36 h pi, barrier integrity was compromised by 211 50% relative to mock-infected cells. However, infection with Delta variant led to drastic 212 reduction of >80% in TEER values after 24 h pi suggesting rapid induction of cell death 213 214 and disruption of epithelial barrier (Fig. 5A). We measured viral titers in the basolateral chamber and, surprisingly, the viral titers were comparable between the Omicron and 215 216 Delta variant suggesting comparable transcytosis of both these variants but significantly higher cytopathic effect of the Delta variant as compared to the Omicron variant (Fig. 217 218 5B). Disruption of cellular junctions was further confirmed by staining the cells with antibodies against SARS-CoV-2 N, occludin and β -catenin. As expected from the TEER 219 220 values, infection with the Delta variant showed large syncytia formation as visualized by 221 N-positive cells and disruption of and reduction in occludin and β -catenin staining (Fig. 5C). Cells infected with the Omicron variant showed fewer infected cells, mild 222 perturbation in junction proteins (Fig. 5C) further confirming the milder effect of this 223 224 variant on epithelial barrier functions and pathogenicity as observed in animal studies by 225 other groups(17, 29).

226

Comparable replication kinetics and neutralization of BA.1 and BA.2 sub-lineages
 Three sub-lineages of Omicron have been identified so far(<u>8</u>, <u>36</u>) and BA.1 and BA.2
 sub-lineages are the circulating virus strains in the third wave in India since November

230 2021 (Supplementary Fig. S2). We isolated both BA.1 and BA.2 sub-lineage viruses from patient samples and performed growth curve analysis of both these sub-lineages 231 as described earlier in Calu-3 cells. We found no difference in the cellular viral RNA 232 233 levels and viral titers in the supernatants at the indicated time-points post-infection (Fig. 6A and 6B). To further verify the potential of antibodies from vaccinated individuals to 234 neutralize both BA.1 and BA.2 lineages, we enrolled 15 subjects (Median age 29; 5 235 Female, 10 Male) who were vaccinated with ChAdOx1 nCoV-19 vaccine in May 2021. 236 237 We collected samples at three time points: i) first sample at one month after complete vaccination (June 2021), ii) a follow-up sample after 6 months (Dec 2021) and iii) a third 238 sample during the ongoing third wave of SARS-CoV-2 infection (Feb 2022). We 239 performed quantitative nucleocapsid (N) and RBD ELISA(13) to monitor antibody levels 240 241 in samples from the three bleeds. Six of the 15 samples had detectable levels of N antibodies (cut off: 15 BAU/mL) post-vaccination suggesting that these subjects had 242 hybrid immunity (infection + vaccination) as the ChAdOx1 nCoV-19 vaccine does not 243 generate N antibodies. The geometric mean titer (GMT) of N-ELISA antibodies reduced 244 from 14.0 (95% CI: 8.4, 23.1) in June 2021 to 11.5 (95% CI: 7.9, 16.6) in Dec 2021 with 245 246 only five positive samples. However, the samples collected during the Omicron surge in Feb 2022 showed a significant increase in N antibodies with a GMT of 53.5 (95% CI: 247 248 19.6, 145.8) with ten positive samples (Fig. 6C). Similar trends were observed with RBD 249 antibodies where we observed an approximate 3-fold in the GMT of RBD antibodies 250 from 266.0 (95% CI: 120.2, 368.1) in June 2021 to 76.5 (95% CI: 36.7, 159.5) in Dec 251 2021. The samples from Omicron wave showed a spike in RBD antibody titers to 935.3 252 (95% CI: 440.4, 1986) (Fig. 6D).

medRxiv preprint doi: https://doi.org/10.1101/2022.01.28.22269990; this version posted June 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

253 To establish virus neutralization titer assays for the Omicron variant, we first performed conventional plaque assays with the virus stocks using both Calu-3 and Vero 254 E6 cells and found delayed and small plaque formation in Calu-3 cells as compared to 255 256 the Delta variant (Supplementary Fig. S3A). However, unlike the Delta variant, the Omicron variant did not produce plaques up to 48 h post-infection in Vero E6 cells. As 257 Calu-3 cells are slow-growing and plaque assays are not amenable for high-throughput 258 259 neutralization assays, we first tested the ability of the Omicron variant to form infectious 260 foci by antibody staining with anti-spike and anti-nucleocapsid antibodies in Vero E6 cells. While the Delta variant formed clear discernable infectious foci with both the 261 antibodies, the same was less distinct with anti-spike antibodies for the Omicron variant 262 although it was countable by the spot reader (Supplementary Fig. S3B). Staining with 263 264 nucleocapsid antibodies produced better foci in the case of Omicron variant but the 265 guality of foci was not comparable with the Delta variant (Supplementary Fig. S3B). We next tested secondary antibodies conjugated with fluorescent dye instead of 266 267 horseradish peroxidase enzyme (HRP) and visualized the infectious foci in fluorescence mode. Use of fluorescence-based detection was far superior to HRP-based enzyme-268 substrate detection for the Omicron variant (Supplementary Fig. S3C). The assay 269 270 showed consistency in performance as measured by the antibody titers of an in-house 271 pooled convalescent reference serum (Supplementary Fig. S3D). We adopted this 272 method for comparing the neutralizing antibody titers against the Delta and Omicron 273 variants. The neutralizing antibody titers for Delta variant as measured by FRNT assay also showed about three-fold reduction from a GMT of 257.5 (95% CI: 145.8, 454.7) in 274 275 June 2021 to 87.5 (49.7, 154.1) in Dec 2021 (Fig.6E). However, as expected from the

276 ELISA titers, the GMT of neutralizing antibodies increased significantly to 914.0 (95% CI: 468.7, 1782) in samples from the third wave in Feb 2022 indicating re-infection in 277 most of these individuals. As shown by us and others(10, 37), the neutralizing antibody 278 titers for Omicron variant was drastically reduced at all the time points relative to that of 279 Delta variant (Fig. 6F). Nine out of 15 samples had FRNT₅₀ value above the level of 280 281 detection after vaccination in June 2021. The GMT of neutralizing antibodies for the Omicron variant was 26.9 (95% CI: 15.6, 46.4) in these samples. The number of 282 283 samples positive for Omicron antibodies reduced to six out of 15 bringing the down the 284 GMT of neutralizing antibodies to 18.3 (95% CI: 11.6, 28.7) by Dec 2021. As expected, the surge in Omicron infections in the study area was reflected in the GMT of 285 286 neutralizing antibodies in samples from Feb 2022 (Fig. 6F). Surprisingly, the samples 287 from Omicron surge showed relatively lower titer, a GMT of 261.9 (95% CI: 113.0, 607.5) as compared to a GMT of 914.0 (95% CI: 468.7, 1782) for the Delta variant 288 suggesting that natural infection with Omicron variant generates significantly higher 289 levels of antibodies to the Delta variant. 290

SARS-CoV-2 sequencing data from the National Capital Region (NCR), our 291 292 study site, showed co-occurrence of B.1.617.2 (Delta) and various AY.* (Delta plus) lineages during the months of September 2021 to December 2021, wherein all AY 293 294 lineages were more in circulation than the parent B.1.617.2 lineage (Supplementary 295 Figure S2). It is important to note that a rise in the cases of Omicron lineages (B.1.529, BA.1 and BA.2) is observed from December 2021 onwards. This is concomitant with the 296 297 arrival of Omicron variant in India and a gradual decrease in circulation of Delta lineage. 298 Delta variant was superseded by Omicron by January 2022. Within Omicron lineages,

299 cases of BA.2 sub-lineage increased/spread at a faster rate compared to other Omicron lineages (BA.1 and B.1.529) (Supplementary Figure S2) which is similar to reports from 300 other countries. This is consistent with the observations that BA.2 lineage has increased 301 rates of transmission (38, 39). We enrolled participants (n=19) who were either COVID-302 19 RT-PCR positive in the ongoing Omicron surge or had symptomatic respiratory 303 304 infection but got no COVID-19 testing done. The GMT of neutralizing antibodies for BA.1 and BA.2 sub-lineages in these samples were 538.1 (95% CI: 338.5, 855.3) and 305 910.6 (95% CI: 608.2, 1363) and this difference was not statistically significant as 306 307 reported by others(40). As we recently reported minimal to no neutralizing antibodies against the Omicron variant in subjects with vaccine-induced or hybrid immunity at the 308 309 beginning of the surge in COVID-19 cases in December 2021(<u>12</u>), our data suggests 310 that enhanced neutralizing antibody titers observed in this study cohort is due to natural exposure to SARS-CoV-2 Omicron variant. 311

312

313 Copper and Iron (II) salts inhibit both Delta and Omicron variant infection

314 Divalent cations play an important role in replication of RNA viruses(41) and previous reports have suggested inhibition of coronavirus replication by Zn salts(42). We 315 established the fluorescence-based SARS-CoV-2 RNA-dependent RNA polymerase 316 317 (RdRp) assay using purified nsp7, nsp8 and nsp12 proteins with minor modifications 318 based on previous reports(43-45). RdRp assays were performed in the presence of 10 319 μM, 100 μM or 1000 μM of CaCl₂/CuCl₂/FeSO₄/ZnSO₄. CaCl₂ did not affect RdRp 320 activity under these conditions. At 1000 µM, CuCl₂ showed about 35% reduction in 321 RdRp activity while FeSO₄ and ZnSO₄ showed 85% and 60% inhibition respectively at

the same concentration (Fig. 7A). At 100 μ M, FeSO₄ showed 25% reduction in activity 322 323 which was significant compared to untreated while ZnSO₄ showed 52% inhibition at this concentration (Fig. 7A). Only ZnSO₄ was capable of inhibiting SARS-CoV-2 RdRp 324 activity albeit by only 22% at 10 μ M (Fig. 7A). The 50% inhibitory concentration (IC₅₀) of 325 ZnSO₄ and FeSO₄ in RdRp assays was 313 µM and 347 µM respectively (Fig. 7B and 326 7C). To further confirm the validity of these *in vitro* inhibition in cell culture, we infected 327 Calu-3 cells with either the Delta variant or the Omicron variant and medium 328 supplemented with 50 µM each of CaCl₂/CuCl₂/FeSO₄/MnCl₂/ZnSO₄ was added after 329 virus adsorption and cells were cultured for 24 h. This concentration of salts was shown 330 to not affect viability of the cells (Supplementary Figure S4). Virus titers in the infected 331 332 culture supernatants were estimated by plaque assays. Contrary to RdRp assay results, ZnSO₄ at 50 µM concentrations failed to show any inhibition of either the Delta or the 333 Omicron variants in Calu-3 cells (Fig. 7D and 7E). Similarly, neither CaCl₂ nor MnCl₂ 334 335 had any impact on virus titers. However, both CuCl₂ and FeSO₄ showed significant inhibition of virus titers. Both these salts inhibited the Delta variant infection by 70% 336 (Fig. 7D) and the effect was even more drastic (>90% inhibition) in the case of Omicron 337 variant (Fig. 7E). Therefore, our results suggest that copper and iron salts may have 338 both direct and indirect antiviral activity against SARS-CoV-2 when added post-339 infection. 340

341

342 **DISCUSSION**

SARS-CoV-2 Delta variant was shown to be more infectious and duration from PCR
 positivity or symptoms with this variant was shorter as compared to other SARS-CoV-2

345 virus strains leading to faster transmission and severe disease. In our study, the Delta variant showed enhanced disruption of epithelial barriers and junction proteins 346 suggesting that the enhanced cytopathic effect and syncytia formation combined with 347 348 the ability to escape from neutralizing antibodies has provided a growth advantage for Delta variant(1, 2, 28). Contrary to the enhanced pathogenicity of the Delta variant, the 349 350 Omicron variant showed lower replication and had milder effect on epithelial barrier 351 functions which correlates with less number of severe cases, hospitalization and lower 352 number of deaths due to COVID-19 in the ongoing third wave of SARS-CoV-2 infections 353 in India which is similar to what has been reported from other countries(46). The clinical 354 samples for this study was collected during the second and third wave of COVID-19 in 355 India during which the Delta and Omicron variants were the predominant circulating 356 virus strains. Cohort data of patients with mild COVID-19 infection has shown that RBD 357 antibodies decay with a half-life of 69 days(47). We observed a three-fold reduction in 358 RBD antibody and neutralizing antibody titers after six months. However, most of the samples had no neutralizing antibodies against the Omicron variant after six months of 359 360 vaccination suggesting that waning neutralizing titers are an important determinant of 361 reinfections and may also contribute to increased susceptibility to new variants of 362 concern that escape pre-existing humoral immunity. The high-throughput neutralizing antibody assay we established in this study enabled us to circumvent the challenges of 363 estimating neutralizing antibody titers for the Omicron variant as it grew poorly and did 364 365 not form distinct plaques or infectious foci like the Delta variant. Currently, BA.1 and 366 BA.2 sub-lineages of the Omicron variant are circulating in India and reports have raised concern about the enhanced pathogenicity or transmissibility of BA.2 sub-lineage 367

medRxiv preprint doi: https://doi.org/10.1101/2022.01.28.22269990; this version posted June 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

368 due to unique mutations in the spike region(39, 48). We show that both BA.1 and BA.2 369 sub-lineages of Omicron variant have comparable replication kinetics in Calu-3 cells. 370 Our sequencing data suggests that the BA.2 sub-lineage of the Omicron variant was the predominant circulating virus at the time of the study and relatively higher levels of 371 neutralizing antibodies to BA.2 was observed in study participants as compared to BA.1 372 373 further confirming that BA.2 may have been the infecting virus. We show that participants who were naturally infected with the Omicron variant generated neutralizing 374 375 antibodies against both BA.1 and BA.2 sub-lineages indicating that exposure to any of 376 the sub-lineages of Omicron would confer cross-protection against other members of 377 the sub-lineage in agreement with other reports (14, 40). Interestingly, higher titers of 378 neutralizing antibodies were observed against the Delta variant which was no longer in 379 circulation indicating a broader cross-protective immune response most likely due to conserved B-cell and T-cell epitopes in the Omicron variant that could have triggered 380 381 the memory responses in people with hybrid immunity(49, 50). Thus, natural infection 382 with Omicron variant may have acted as a booster eliciting cross-reacting antibodies across Omicron sub-lineages and other VoCs in young adults. 383

384

Several studies have reported that interferons expressed in the lower respiratory tract contribute to tissue damage, impair regeneration of lung epithelium and contribute to morbidity observed in COVID-19 patients(51, 52). We observed similar levels of induction of *IFN-β* and *IFN-λ1* and the downstream effectors namely *ISG15* and *OAS1* in cells infected with the Delta variant and with the ancestral B.6 lineage virus suggesting that suppression of innate immune responses is not a contributory factor in

391 increased pathogenesis observed with the Delta variant. Despite lower levels of infection, the Omicron variant induced higher levels of interferon pathway genes. Since 392 the Omicron variant was shown to mostly replicate in the upper respiratory tract(53, 54). 393 this suggests that interferon-dependent antiviral responses may limit viral replication 394 and further tissue spread thus resulting in milder symptoms and resolution of infection. 395 396 Therefore, interferon therapy targeted towards the upper respiratory tract may be more effective in the case of infection with the Omicron variant. In addition to interferons, our 397 results suggest that supplementation with copper and iron salts may also augment the 398 399 antiviral strategy for SARS-CoV-2 as both CuCl₂ and FeSO₄ inhibited both the Delta and Omicron variants in Calu-3 cells. 400

401

Vaccines have played a major role in bringing the COVID-19 pandemic under control. 402 However frequent emergence of SARS-CoV-2 variants requires adjunct approaches to 403 404 deal with infections. Micronutrient supplementation could be an effective and safe strategy. Ferric ammonium citrate (FAC) was shown to inhibit a number of RNA viruses 405 including Influenza A virus, Zika virus and Hepatitis C virus in both cell culture and 406 407 animal models and it was shown that treatment with FAC perturbed endosomal release of the internalized virus in the case of Influenza A virus(55). SARS-CoV-2 nsp12 has 408 409 been shown to bind Fe and Iron-Sulfur cluster binding was required for optimal activity 410 of the RdRp(56). However, there have been no direct demonstration of the effect of Fe 411 salts on either the RdRp activity in vitro on in lung epithelial cells. We show here that FeSO₄ inhibited both RdRp activity and infection in Calu-3 cells. The 412 inhibitory concentration in cell culture was much below the *in vitro* IC₅₀ concentrations. Contrary to 413

414 our findings, iron overload is considered as a risk factor for severe COVID-19 disease and iron chelation has been proposed as a treatment option(57) (58). Therefore, the 415 exact mechanism of action behind inhibition of SARS-CoV-2 infection by FeSO4 416 warrants further investigation. Interestingly, CuCl₂ which inhibited RdRp activity at 1 mM 417 also inhibited virus infection in Calu-3 cells at 20 times below this concentration 418 419 indicating that both Fe an Cu ions may act on SARS-CoV-2 both directly and via host pathways. Previous reports have shown that copper-coated surfaces can inactivate 420 421 SARS-CoV-2(59) and other enveloped and non-enveloped viruses are susceptible to copper ions either due to direct effect of copper ions on viral particles or viral genome or 422 due to induction of reactive oxygen species. Therefore, copper supplementation during 423 424 viremic phase may further augment antiviral strategies for COVID-19(60-62). Zinc 425 acetate, in combination with zinc ionophore pyrithione, was shown to inhibit SARS-CoV-426 1 infection in Vero E6 cells and zinc ions was shown to directly inhibit RdRp activity of 427 SARS-CoV-1(42). SARS-CoV-2 proteome encodes for a number of metalloproteins 428 including zinc-binding proteins such as nsp2, nsp9, nsp10/16 complex, nsp12 and proofreading exoribonuclease nsp14 (Please see Uniprot ID: P0DTD1 · R1AB_SARS2). 429 Some of the critical aspects of viral replication such as RdRp activity, 2'-O methylation, 430 capping depends on intracellular zinc(63, 64). Zinc ejection from some of these enzymes 431 432 has been proposed as an attractive antiviral target(65). However, despite ZnSO₄ inhibiting the activity of SARS-CoV-2 RdRp in vitro, we saw no effect on SARS-CoV-2 433 434 Delta and Omicron variants at 50 µM concentration. Whether higher concentrations of 435 zinc salts are required to achieve significant inhibition of these variants in cell culture 436 needs further investigation.

437

438 **ONLINE METHODS**

439 Human Ethics

The study was approved by the Institutional Ethics Committee for human research at ESIC Hospital and Medical College (No.134/R/10/IEC/22/2021/02) and THSTI (THS 1.8.1/ (93)). Informed consent was obtained from all the participants.

443

444 Human Samples

ChAdOx1 nCoV-19 cohort: Subjects (age 25-46) visiting ESIC Medical College & 445 Hospital, Faridabad for vaccination were enrolled in the study after obtaining written 446 informed consent. About 4 ml of whole blood was collected for serum preparation four 447 weeks after the first and second dose of vaccination and a follow-up sample was 448 collected after six months. Nasopharyngeal/Oropharyngeal (NP/OP) swabs were 449 collected from patients with symptoms of COVID-19 infection. Total RNA was isolated to 450 451 detect SARS-CoV-2 using COVIDsure multiplex real-time RT-PCR kit (Trivitron Healthcare) either at Employees State Insurance Corporation (ESIC) Medical College & 452 Hospital or at the bioassay laboratory Translational Health Science and Technology 453 454 Institute, Faridabad. Clinical presentations were mild to moderate fever, dry cough, and 455 loss of sense of smell and taste. All COVID-19 positive patients were self-isolated and 456 recovered without any need for clinical intervention or hospitalization. A follow-up blood sample was collected after 3-4 weeks post-recovery in both second (May 2021) and 457 third wave (Feb 2022). 458

459

460 Cells and Viruses

Calu-3 cells and Vero E6 cells were procured from American Type Culture Collection 461 (ATCC) and European Collection of Authenticated Cell Cultures (ECACC) respectively. 462 463 Both cell lines were maintained in Dulbecco's Modified Eagle Medium (DMEM) (HiMedia) supplemented with 10% fetal bovine serum (FBS), 100 units/ml of Penicillin-464 Streptomycin-Glutamine (PSG), and 1X non-essential amino acid (NEAA). In addition to 465 this, 25 mM HEPES was added to the Vero E6 culture medium. Different variants of 466 SARS-CoV-2 i.e., ancestral (B.6, Genbank: MW422884.1), kappa (B.1.617.1, Genbank: 467 MZ356902.1), delta (B.1.617.2, Genbank: MZ356566.1), and omicron (B.1.529; BA.1 468 469 GISAID: EPI ISL 6716902 and BA.2 GISAID ID: EPI ISL 87638432 sub-lineages) were propagated in Calu-3 cells and passaging was limited to five passages. 470

471

472 Growth curve experiment

All experiments with infectious SARS-CoV-2 virus were performed at the infectious 473 474 disease research facility, which is a biosafety level-3 laboratory. Calu-3 cells were seeded in 48-well or 24-well plates and infected with indicated SARS-CoV-2 virus 475 isolates two days post-seeding. Infected culture supernatants were collected at 476 477 indicated time points to estimate viral titers by plaque assay on Vero E6 cells. Total RNA was extracted from cells collected at respective time points and viral copy 478 numbers (N gene) were estimated by guantitative RT-PCR using RNAse P gene for 479 480 normalization as described previously(66).

481

482 Plaque assay Method

483 Vero E6 cells were used for virus titration by plaque assay method. The supernatants were collected from infected cells at indicated time points. The supernatants were ten-484 fold diluted using growth medium with 2% FBS. After 1h of viral adsorption, virus 485 486 inoculum was removed. Overlay medium with 0.5% carboxymethylcellulose (CMC) was added to the cells. The plates were incubated at 37° C for 48 h for all SARS-CoV-2 487 variants except omicron where the incubation period was 72 h. After the incubation 488 period, cells were fixed with 3.7% formaldehyde solution followed by incubation for 10 489 min at room temperature (RT). Cells were stained with crystal violet solution and 490 491 plaques were observed.

492

493 Trans-epithelial electrical resistance (TEER) and confocal microscopy

494 Calu-3 cells were seeded at 30,000 on 3 µm pore size transwell inserts (Corning - 3415) and grown for 21 days. TEER was monitored on alternate days using a chopstick 495 electrode (Millipore) and the medium was changed on the same day. On day 22 post-496 497 seeding, cells were infected with indicated variants of SARS-CoV-2 at 0.3 MOI. After 1 h of viral adsorption, virus inoculum was removed and cells were washed twice with 1X 498 PBS. Growth medium with 10% FBS was added to the cells. TEER was monitored at 499 500 indicated time points. At 48 h pi, culture inserts were washed with cold 1X PBS and 501 incubated with cold methanol at -20°C for 20 minutes. Cells were further incubated with IMF buffer (20 mM HEPES, pH 7.5, 0.1% Triton X-100, 150 mM sodium chloride, 5 mM 502 EDTA and 0.02% sodium azide as a preservative) for 5 min at room temperature (RT) 503 and all further washes were performed with IMF buffer. Non-specific antibody binding 504 505 sites were blocked by incubating cells with IMF buffer containing 2% normal goat serum

506 for 10 min at RT. Membranes were cut out using a scalpel blade and transferred to a 48-well plate. Cells were washed three times followed by incubation with antibodies 507 against SARS-CoV-2 nucleocapsid, occludin, and β -catenin in IMF buffer for 1 h at RT. 508 509 Cells were washed followed by incubation with secondary antibodies tagged with Alexa Fluor 488/568/633 (Molecular probes) for 30 min at RT by avoiding exposure to light. 510 Cells were washed with IMF buffer three times and stained with DAPI at 1:10,000 511 dilution for 10 min. Cells were washed with PBS, mounted on glass slide using antifade 512 513 solution (Molecular probes), and images were captured at 100X magnification using FV3000 confocal microscope (Olympus). Acquired images were processed using 514 515 CellSens software (Olympus) and projections of Z-stack (maximum intensity) are shown in figures. 516

517

518 Focus-forming units (FFU) assay

The supernatants were collected from infected cells at indicated time points. The 519 520 supernatants were ten-fold diluted using growth medium with 2% FBS. After 1h of viral virus inoculum medium with 1.5% 521 adsorption. was removed. Overlay carboxymethylcellulose (CMC) for all SARS-CoV-2 variants except for Omicron where 522 1% CMC was used. The plates were incubated at 37° C for 28 h for omicron and 24 h 523 for all other SARS-CoV-2 variants. After incubation time, cells were fixed with 524 formaldehyde solution followed by permeabilization with IMF buffer for 20 min 525 526 incubation. Further, cells were stained with anti-spike RBD rabbit polyclonal antibody dilution at a dilution of 1:2000 for 1 h, followed by incubation with secondary antibody 527 528 i.e., Alexa flour 488-conjugated anti-rabbit antibody at 1:500 dilution for 1 h. For omicron

isolate, anti-nucleocapsid primary antibody was used at a dilution of 1:2000. This was followed by incubation with secondary antibody i.e., Alexa flour 488-conjugated goat anti-mouse IgG secondary antibody at 1:500 dilution. Fluorescent foci indicating infected cells were observed and counted using AIDiSpot reader using FITC channel.

533

534 Western blot

At indicated time points, cells were washed twice with cold PBS on ice and were 535 collected in 200 µl of 1X laemmli buffer with protease inhibitor mix and 1 mM PMSF. 536 Lysates were incubated on ice for 10 min and sonicated (amplitude: 30%, time: 5 sec 537 ON/10 sec OFF, total cycles: 10) on ice. Cell lysates were centrifuged at 13,000 x g for 538 15 min at 4 °C. 5 µl of each sample was resolved on 12% SDS-PAGE. Gels were 539 540 transferred onto PVDF membrane for 2 h and the SARS-CoV-2 infection was analyzed 541 by probing the blot with the SARS-CoV-2 nucleocapsid antibody. GAPDH antibody was used as a loading control. Primary antibody incubation was followed by HRP-conjugated 542 543 secondary antibodies. Luminol-based chemiluminescent substrate was added to the blots and signals were detected using a gel documentation system (Azure biosystems 544 C400). 545

546

547 Virus entry experiment

Calu-3 cells were infected with the above-indicated variants of SARS-CoV-2 at 5 MOI. After 1 h of viral adsorption, the virus inoculum was removed and cells were washed with 1X PBS. Cells were trypsinized and collected in complete growth medium and centrifuged at 200 x g for 5 min. The supernatants were discarded and the cell pellets

were washed twice with 1X PBS followed by centrifugation. In the final step, the cell pellets were collected in 350 µl lysis buffer. Viral copy numbers were estimated as described in the above section.

555

556 **Quantitative RT-PCR Assay**

Calu-3 cells were infected with ancestral, delta, and omicron variants of SARS-CoV-2 at 557 a MOI of 0.3. At indicated time points, the supernatant was collected for estimating viral 558 559 titres by plaque assay, and cells were collected in lysis buffer provided in the RNA isolation kit as described in the above section. For interferon pathway, 500 ng RNA was 560 561 used to erase genomic DNA and reverse transcribed using PrimeScript RT reagent kit with gDNA eraser kit. The indicated genes were quantitated by SYBR green chemistry 562 563 and GAPDH was used as housekeeping control gene for normalization. The list of primers used is provided in the key resources table. Data were analyzed using the 564 $\Delta\Delta C_T$ method, where C_T is cycle threshold. 565

566

567 **TEER in air-liquid interface condition and confocal microscopy**

Calu-3 cells were seeded at a density of 30,000 cells in 3 µm pore size polycarbonate membranes in 24 well-plate with corresponding 200 µl culture medium on the apical side and 800 µl culture medium was added into the basolateral chamber. Cells were left to grow submerged for 8 days. The culture medium was changed on alternate days and TEER values were monitored. On day 9, the medium was removed from the apical chamber to obtain air-liquid interface (ALI) conditions. Cells were cultured in ALI conditions for 20 days. After obtaining stable TEER values, on day 21, cells were

575 washed with 1X Hanks' balanced salt solution (HBSS). Cells were infected with either the Delta or the Omicron variants of SARS-CoV2 at 0.3 MOI. After 1 h of viral 576 adsorption, cells were washed twice with HBSS, and culture medium was added to the 577 578 basolateral side. To assess the effect of SARS-CoV-2 on epithelial cells barrier, TEER was monitored at indicated time points. Supernatants were collected from basolateral 579 surface for measuring viral titres. At 36 h pi, cells were washed with cold PBS and fixed 580 in ice-cold methanol for 20 min at -20°C. The cells were stained against junction 581 proteins along with nucleocapsid antibodies as described above in the confocal 582 583 microscopy section.

584

585 Quantitative Nucleoprotein (N) and RBD ELISA

586 ELISA for nucleocapsid (N) and recombinant spike protein receptor-binding domain 587 (RBD) was performed as described earlier. Detailed method description is provided in 588 previous reports(13, 67).

589

590 Virus microneutralization assay

591 Virus microneutralization assay by focus reduction neutralization titer (FRNT) assay

using indicating virus isolates was performed as described earlier($\underline{13}$, $\underline{67}$).

593

594 **RNA-dependent RNA polymerase (RdRp) activity assay**

The Quant-iT[™] PicoGreen[®] dsDNA reagent was used to establish a fluorophore-based
RdRp activity system. Adenosine 5'-triphosphate (ATP) was purchased from Sigma–
Aldrich. RdRp RNA template with self-hairpin primer used for RdRp assays in this study

598	as fo	llowing	5'-
599	υυυυυυυυυυυυυυυυυυυ	JUUUUAACAGGUUCUAGAACCUGUU-3'	
600	(Eurofins). Each reaction (final volume 30	µl) was carried out in 96 well black flat-bott	om
601	plates in triplicates. 150 nM of nsp12 and	1.5 μ M of nsp7 & 8 was mixed in a react	ion
602	buffer (50 mM HEPES pH 8, 5 mM DTT	r, 10 mM KCl, 2 mM MgCl ₂ , 2 mM MnCl ₂)	to
603	make up to 15 µl. Indicated concentration	ns of ZnSO ₄ , CaCl ₂ , CuCl ₂ , and 5 μ l of 200	nM
604	poly-U were added to the reaction buffer	. The mixture was incubated at 30 \square C fo	r 5
605	min. The reactions were initiated by addir	ng 5 μ l of 500 μ M ATP to the reaction mixtu	ıre.
606	The plate was incubated at 30 \square C for 30 i	min. The reaction was stopped by adding 20) µl
607	EDTA (100 mM). The Quant-iT™ PicoG	reen $^{ m e}$ dsDNA reagent was diluted to 1/800) in
608	1X TE buffer (10 mM Tris-HCl, 1 mM E	DTA, pH 7.5) and 50 μ l of this reagent v	vas
609	added to each well of the plate. The plat	e was incubated in the dark for 30 min at I	RT.
610	The fluorescence signal was assessed us	sing microplate reader at excitation of 485	nm
611	and emission of 582 nm.		

612

613 Inhibition experiments

Calu-3 cells were seeded at a density of 90,000 per well in 48 well-plate. Cells were infected with indicated SARS-CoV2 variants at 0.3 MOI. After viral adsorption, cells were washed twice with 1X PBS. CaCl₂, CuCl₂, FeSO₄, MnCl₂, and ZnSO₄ were added each in growth medium in serum-free condition to a final concentration of 50 μ M. After 24 h pi, supernatants were collected and viral titers were measured by plaque assay.

619

620 Statistical tests

621	Data were analysed and charts were prepared using GraphPad Prism software. All
622	experiments were performed with two or more replicates and graphs have been
623	prepared representing data from at least two independent experiments. Figure legends
624	indicate error bars and statistical tests conducted for estimating P values.
625	
626	Data availability
627	All the data are presented in this manuscript. Source data will be made available upon
628	request.
629	
630	ACKNOWLEDGEMENTS
631	We thank all the members of bioassay lab, COVID-19 testing team, Amresh Kumar
632	Singh Maniram and other members of the Clinical and Cellular Virology lab for technical
633	support. We thank Neha Garg and Shamsher Singh for data management. We thank all
634	the patients who consented to participate in the study.

635

636 **AUTHOR CONTRIBUTIONS**

JS, AP, AA, MB, PK and KP performed all cell culture and infection experiments. CR purified recombinant proteins and performed the *in vitro* RdRp assays. PC, PD, RM, PM performed SARS-CoV-2 genome sequencing and analysis. AKP supervised and coordinated the study at the clinical site and contributed reagents. RP designed the sequencing experiments, supervised the team and analyzed the data. GRM conceived the study, designed the experiments, and analyzed the data. JS, AP, AA and GRM

643 wrote the manuscript. All authors have reviewed and approved the final version of the 644 manuscript.

645

646 **FUNDING INFORMATION**

- This work was supported by the Department of Biotechnology (DBT) grants through
- 648 IndCEPI Mission (BT/MB/CEPI/2016), Translational Research Program
- 649 (BT/PR30159/MED/15/188/2018) and BT/PR40384/COT/142/5/2020. Funding support
- was also obtained from Global Immunology and Immune Sequencing for Epidemic
- 651 Response (INV-030592). RP acknowledges funding support from IUSSTF (CLP-0033)
- and BMGF (CLP-0036). The funders had no role in study design, data collection and
- 653 interpretation or the decision to submit the work for publication.

654

655 **CONFLICT OF INTEREST STATEMENT**

The authors have declared that no conflict of interest exists.

657

658 **REFERENCES**

Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al.
 Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at
 June 2021. Euro Surveill. 2021 Jun;26(24). PubMed PMID: 34142653. Pubmed Central
 PMCID: PMC8212592. Epub 2021/06/19.

Fisman DN, Tuite AR. Progressive Increase in Virulence of Novel SARS-CoV-2
 Variants in Ontario, Canada. medRxiv. 2021:2021.07.05.21260050.

Li B, Deng A, Li K, Hu Y, Li Z, Xiong Q, et al. Viral infection and transmission in a
large well-traced outbreak caused by the Delta SARS-CoV-2 variant. medRxiv.
2021:2021.07.07.21260122.

MIcochova P, Kemp S, Dhar MS, Papa G, Meng B, Mishra S, et al. SARS-CoV-2
B.1.617.2 Delta variant emergence, replication and sensitivity to neutralising antibodies.
bioRxiv. 2021:2021.05.08.443253.

5. Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv. 2021:2021.05.22.21257658.

6. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals. bioRxiv. 2021:2021.05.26.445838.

- 578 7. Supasa P, Zhou D, Dejnirattisai W, Liu C, Mentzer AJ, Ginn HM, et al. Reduced
 579 neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell.
 580 2021 Apr 15;184(8):2201-11 e7. PubMed PMID: 33743891. Pubmed Central PMCID:
 581 PMC7891044. Epub 2021/03/22.
- 8. Mahase E. Covid-19: What do we know about omicron sublineages? BMJ. 2022
 Feb 11;376:o358. PubMed PMID: 35149516. Epub 20220211.
- 684
 9. Cele S, Jackson L, Khan K, Khoury DS, Moyo-Gwete T, Tegally H, et al. SARS685 CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited
 686 neutralization and requires ACE2 for infection. medRxiv. 2021 Dec 11. PubMed PMID:
 687 34909788. Pubmed Central PMCID: PMC8669855. Epub 20211211.
- 10. Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, et al. Reduced
 neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.
 Lancet. 2021 Dec 20. PubMed PMID: 34942101. Pubmed Central PMCID:
 PMC8687667. Epub 20211220.
- Iketani S, Liu L, Guo Y, Liu L, Huang Y, Wang M, et al. Antibody Evasion
 Properties of SARS-CoV-2 Omicron Sublineages. bioRxiv. 2022:2022.02.07.479306.
- Medigeshi GR, Batra G, Murugesan DR, Thiruvengadam R, Chattopadhyay S,
 Das B, et al. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies
 induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post
 697 6-months. eBioMedicine. 2022;78.
- Singh J, Shaman H, Anantharaj A, Singh B, Pargai K, Kumar P, et al. Infection
 with Omicron variant generates neutralizing antibodies to BA.1 and BA.2 sub-lineages
 and induces higher levels of cross-neutralizing antibodies to Delta variant. medRxiv.
 2022:2022.01.28.22269990.
- Yu J, Collier AY, Rowe M, Mardas F, Ventura JD, Wan H, et al. Neutralization of
 the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. N Engl J Med. 2022 Mar 16.
 PubMed PMID: 35294809. Epub 20220316.
- 15. Carroll T, Fox D, van Doremalen N, Ball E, Morris MK, Sotomayor-Gonzalez A, et
 al. The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral
 B.1 (614G) in Syrian hamsters. PLoS Pathog. 2022 Feb;18(2):e1009914. PubMed
 PMID: 35143587. Pubmed Central PMCID: PMC8865701. Epub 20220210.
- 16. Escalera A, Gonzalez-Reiche AS, Aslam S, Mena I, Laporte M, Pearl RL, et al.
 Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and
 virus transmission. Cell Host Microbe. 2022 Mar 9;30(3):373-87 e7. PubMed PMID:
 35150638. Pubmed Central PMCID: PMC8776496. Epub 20220121.
- 17. Halfmann PJ, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer SM, et
 al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters.
 Nature. 2022 Mar;603(7902):687-92. PubMed PMID: 35062015. Epub 20220121.

Port JR, Yinda CK, Avanzato VA, Schulz JE, Holbrook MG, van Doremalen N, et
al. Increased small particle aerosol transmission of B.1.1.7 compared with SARS-CoV-2
lineage A in vivo. Nat Microbiol. 2022 Feb;7(2):213-23. PubMed PMID: 35017676. Epub
20220111.

19. Saito A, Irie T, Suzuki R, Maemura T, Nasser H, Uriu K, et al. Enhanced
fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature. 2022
Feb;602(7896):300-6. PubMed PMID: 34823256. Pubmed Central PMCID:
PMC8828475. Epub 20211125.

20. Ulrich L, Halwe NJ, Taddeo A, Ebert N, Schon J, Devisme C, et al. Enhanced
fitness of SARS-CoV-2 variant of concern Alpha but not Beta. Nature. 2022
Feb;602(7896):307-13. PubMed PMID: 34937050. Pubmed Central PMCID:
PMC8828469. Epub 20211222.

Laskar R, Ali S. Phylo-geo-network and haplogroup analysis of 611 novel
coronavirus (SARS-CoV-2) genomes from India. Life Sci Alliance. 2021 May;4(5).
PubMed PMID: 33727249. Pubmed Central PMCID: PMC7994317. Epub 2021/03/18.

731 Pattabiraman C, Habib F, P KH, Rasheed R, Prasad P, Reddy V, et al. Genomic 22. 732 epidemiology reveals multiple introductions and spread of SARS-CoV-2 in the Indian state of Karnataka. PLoS One. 2020;15(12):e0243412. PubMed PMID: 33332472. 733 Pubmed Central PMCID: PMC7746284 participate as a volunteer in this study and his 734 735 employer neither had access to data, nor any say in the design of the study or the decision to publish. This does not alter our adherence to PLOS ONE policies on sharing 736 737 data and materials. All other authors are employees of state (PD, PK) or central government. The employers had no role in the design of the study or the decision to 738 publish. The authors declare that they do not have any other financial or non-financial 739 740 relationships that could present a conflict of interest. Epub 2020/12/18.

Anantharaj A, Gujjar S, Kumar S, Verma N, Wangchuk J, Khan NA, et al.
Kinetics of viral load, immunological mediators and characterization of a SARS-CoV-2
isolate in mild COVID-19 patients during acute phase of infection. medRxiv.
2020:2020.11.05.20226621.

24. Dhar MS, Marwal R, Radhakrishnan V, Ponnusamy K, Jolly B, Bhoyar RC, et al.
Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in
Delhi, India. medRxiv. 2021:2021.06.02.21258076.

Zhu N, Wang W, Liu Z, Liang C, Wang W, Ye F, et al. Morphogenesis and
cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells. Nat
Commun. 2020 Aug 6;11(1):3910. PubMed PMID: 32764693. Pubmed Central PMCID:
PMC7413383. Epub 2020/08/09.

Liu Y, Liu J, Johnson BA, Xia H, Ku Z, Schindewolf C, et al. Delta spike P681R
mutation enhances SARS-CoV-2 fitness over Alpha variant. bioRxiv. 2021 Sep 5.
PubMed PMID: 34462752. Pubmed Central PMCID: PMC8404900. Epub 20210905.

MIcochova P, Kemp S, Dhar MS, Papa G, Meng B, Ferreira I, et al. SARS-CoV-2
B.1.617.2 Delta variant replication and immune evasion. Nature. 2021 Sep 6. PubMed
PMID: 34488225. Epub 2021/09/07.

28. Li B, Deng A, Li K, Hu Y, Li Z, Xiong Q, et al. Viral infection and transmission in a
large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. medRxiv.
2021:2021.07.07.21260122.

29. Suzuki R, Yamasoba D, Kimura I, Wang L, Kishimoto M, Ito J, et al. Attenuated
fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. 2022
Mar;603(7902):700-5. PubMed PMID: 35104835. Epub 20220201.

30. Bojkova D, Widera M, Ciesek S, Wass MN, Michaelis M, Cinatl J, Jr. Reduced
interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta
variant of SARS-CoV-2 isolates. Cell Res. 2022 Mar;32(3):319-21. PubMed PMID:
35064226. Pubmed Central PMCID: PMC8781709. Epub 20220121.

31. Zhao H, Lu L, Peng Z, Chen LL, Meng X, Zhang C, et al. SARS-CoV-2 Omicron
variant shows less efficient replication and fusion activity when compared with Delta
variant in TMPRSS2-expressed cells. Emerg Microbes Infect. 2022 Dec;11(1):277-83.
PubMed PMID: 34951565. Pubmed Central PMCID: PMC8774049.

32. Vanderheiden A, Ralfs P, Chirkova T, Upadhyay AA, Zimmerman MG, Bedoya S,
et al. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway
Epithelial Cultures. J Virol. 2020 Sep 15;94(19). PubMed PMID: 32699094. Pubmed
Central PMCID: PMC7495371. Epub 2020/07/24.

33. Schroeder S, Pott F, Niemeyer D, Veith T, Richter A, Muth D, et al. Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics. Lancet Microbe.
2021 May;2(5):e210-e8. PubMed PMID: 33969329. Pubmed Central PMCID: PMC8096348. Epub 20210304.

780 34. Anantharaj A, Gujjar S, Verma N, Khan NA, Shaman H, Sharanabasava P, et al. Resolution of viral load in mild COVID-19 patients is associated with both innate and 781 adaptive 782 immune responses. Journal of Clinical Virology. 2022 2022/01/01/:146:105060. 783

35. Bojkova D, Rothenburger T, Ciesek S, Wass MN, Michaelis M, Cinatl J. SARSCoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment.
bioRxiv. 2022:2022.01.20.477067.

36. Desingu PA, Nagarajan K, Dhama K. Emergence of Omicron third lineage BA.3
and its importance. Journal of Medical Virology. 2022;94(5):1808-10.

37. Medigeshi G, Batra G, Murugesan DR, Thiruvengadam R, Chattopadhyay S, Das
B, et al. Sub-optimal Neutralisation of Omicron (B.1.1.529) Variant by Antibodies
induced by Vaccine alone or SARS-CoV-2 Infection plus Vaccine (Hybrid Immunity)
post 6-months. medRxiv. 2022:2022.01.04.22268747.

38. Lyngse FP, Kirkeby CT, Denwood M, Christiansen LE, Mølbak K, Møller CH, et
al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence
from Danish Households. medRxiv. 2022:2022.01.28.22270044.

796 39. Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, et al. Virological 797 characteristics of SARS-CoV-2 BA.2 variant. bioRxiv. 2022:2022.02.14.480335.

40. Arora P, Zhang L, Rocha C, Sidarovich A, Kempf A, Schulz S, et al. Comparable
neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3. The
Lancet Infectious Diseases.

41. Chaturvedi UC, Shrivastava R. Interaction of viral proteins with metal ions: role in maintaining the structure and functions of viruses. FEMS Immunol Med Microbiol. 2005

Feb 1;43(2):105-14. PubMed PMID: 15681139. Pubmed Central PMCID: PMC7110337.
42. te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert

MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc

ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010 Nov

- 4;6(11):e1001176. PubMed PMID: 21079686. Pubmed Central PMCID: PMC2973827.
 Epub 2010/11/17.
- 43. Hillen HS, Kokic G, Farnung L, Dienemann C, Tegunov D, Cramer P. Structure

of replicating SARS-CoV-2 polymerase. Nature. 2020 Aug;584(7819):154-6. PubMed
 PMID: 32438371. Epub 20200521.

- 44. Shimizu H, Saito A, Mikuni J, Nakayama EE, Koyama H, Honma T, et al. Discovery of a small molecule inhibitor targeting dengue virus NS5 RNA-dependent RNA polymerase. PLOS Neglected Tropical Diseases. 2019;13(11):e0007894.
- 45. Eydoux C, Fattorini V, Shannon A, Le TT, Didier B, Canard B, et al. A
 fluorescence-based high throughput-screening assay for the SARS-CoV RNA synthesis
 complex. J Virol Methods. 2021 Feb;288:114013. PubMed PMID: 33166547. Pubmed
 Central PMCID: PMC7833800. Epub 20201106.
- 46. Nealon J, Cowling BJ. Omicron severity: milder but not mild. The Lancet. 2022;399(10323):412-3.
- 47. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological
 memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Feb
 5;371(6529). PubMed PMID: 33408181. Pubmed Central PMCID: PMC7919858. Epub
- 824 **20210106**.
- 48. Chen J, Wei GW. Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant. ArXiv. 2022 Feb 10. PubMed PMID: 35169598. Pubmed Central PMCID: PMC8845508. Epub 20220210.
- 49. Gao Y, Cai C, Grifoni A, Muller TR, Niessl J, Olofsson A, et al. Ancestral SARSCoV-2-specific T cells cross-recognize the Omicron variant. Nat Med. 2022 Jan 14.
 PubMed PMID: 35042228. Epub 20220114.
- 50. GeurtsvanKessel CH, Geers D, Schmitz KS, Mykytyn AZ, Lamers MM, Bogers S,
 et al. Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19
 vaccine recipients. Sci Immunol. 2022 Feb 3:eabo2202. PubMed PMID: 35113647.
 Epub 20220203.
- Broggi A, Ghosh S, Sposito B, Spreafico R, Balzarini F, Lo Cascio A, et al. Type
 III interferons disrupt the lung epithelial barrier upon viral recognition. Science. 2020
 Aug 7;369(6504):706-12. PubMed PMID: 32527925. Pubmed Central PMCID:
 PMC7292499. Epub 2020/06/13.
- 52. Major J, Crotta S, Llorian M, McCabe TM, Gad HH, Priestnall SL, et al. Type I
 and III interferons disrupt lung epithelial repair during recovery from viral infection.
 Science. 2020 Aug 7;369(6504):712-7. PubMed PMID: 32527928. Pubmed Central
 PMCID: PMC7292500. Epub 2020/06/13.
- 53. Hui KPY, Ho JCW, Cheung MC, Ng KC, Ching RHH, Lai KL, et al. SARS-CoV-2
 Omicron variant replication in human bronchus and lung ex vivo. Nature. 2022
 Mar;603(7902):715-20. PubMed PMID: 35104836. Epub 20220201.
- 846 54. McMahan K, Giffin V, Tostanoski LH, Chung B, Siamatu M, Suthar MS, et al.
 847 Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters. Med. 2022
 848 2022/04/08/;3(4):262-8.e4.
- ⁸⁴⁹ 55. Wang H, Li Z, Niu J, Xu Y, Ma L, Lu A, et al. Antiviral effects of ferric ammonium ⁸⁵⁰ citrate. Cell Discov. 2018;4:14. PubMed PMID: 29619244. Pubmed Central PMCID:
- 851 PMC5871618. Epub 20180327.

56. Maio N, Lafont BAP, Sil D, Li Y, Bollinger JM, Jr., Krebs C, et al. Fe-S cofactors
in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets.
Science. 2021 Jul 9;373(6551):236-41. PubMed PMID: 34083449. Pubmed Central
PMCID: PMC8892629. Epub 20210603.

Bastin A, Shiri H, Zanganeh S, Fooladi S, Momeni Moghaddam MA, Mehrabani
M, et al. Iron Chelator or Iron Supplement Consumption in COVID-19? The Role of Iron
with Severity Infection. Biol Trace Elem Res. 2021 Nov 25. PubMed PMID: 34825316.
Pubmed Central PMCID: PMC8614629. Epub 20211125.

- 58. Habib HM, Ibrahim S, Zaim A, Ibrahim WH. The role of iron in the pathogenesis
 of COVID-19 and possible treatment with lactoferrin and other iron chelators. Biomed
 Pharmacother. 2021 Apr;136:111228. PubMed PMID: 33454595. Pubmed Central
 PMCID: PMC7836924. Epub 20210113.
- 59. Bryant C, Wilks SA, Keevil CW. Rapid inactivation of SARS-CoV-2 on copper touch surfaces determined using a cell culture infectivity assay. bioRxiv. 2021:2021.01.02.424974.
- 60. Govind V, Bharadwaj S, Sai Ganesh MR, Vishnu J, Shankar KV, Shankar B, et
 al. Antiviral properties of copper and its alloys to inactivate covid-19 virus: a review.
 BioMetals. 2021 2021/12/01;34(6):1217-35.
- 61. Raha S, Mallick R, Basak S, Duttaroy AK. Is copper beneficial for COVID-19 patients? Medical Hypotheses. 2020 2020/09/01/;142:109814.
- 872 62. Sagripanti JL, Routson LB, Lytle CD. Virus inactivation by copper or iron ions
 873 alone and in the presence of peroxide. Appl Environ Microbiol. 1993 Dec;59(12):4374-6.
 874 PubMed PMID: 8285724. Pubmed Central PMCID: PMC195916.
- 875 63. Viswanathan T, Misra A, Chan SH, Qi S, Dai N, Arya S, et al. A metal ion orients
 876 SARS-CoV-2 mRNA to ensure accurate 2'-O methylation of its first nucleotide. Nat
 877 Commun. 2021 Jun 2;12(1):3287. PubMed PMID: 34078893. Pubmed Central PMCID:
 878 PMC8172916. Epub 20210602.
- 879 64. Bouvet M, Lugari A, Posthuma CC, Zevenhoven JC, Bernard S, Betzi S, et al.
 880 Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes. J
 881 Biol Chem. 2014 Sep 12;289(37):25783-96. PubMed PMID: 25074927. Pubmed Central
 882 PMCID: PMC4162180. Epub 20140729.
- 65. Chen T, Fei CY, Chen YP, Sargsyan K, Chang CP, Yuan HS, et al. Synergistic
 Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir. ACS
 Pharmacol Transl Sci. 2021 Apr 9;4(2):898-907. PubMed PMID: 33855277. Pubmed
 Central PMCID: PMC8009100. Epub 20210326.
- Anantharaj A, Das SJ, Sharanabasava P, Lodha R, Kabra SK, Sharma TK, et al.
 Visual Detection of SARS-CoV-2 RNA by Conventional PCR-Induced Generation of
 DNAzyme Sensor. Front Mol Biosci. 2020 2020-December-23;7(444):586254. PubMed
 PMID: 33425988. Pubmed Central PMCID: PMC7793695. Epub 2021/01/12. English.
- 67. Das S, Singh J, Shaman H, Singh B, Anantharaj A, Sharanabasava P, et al. Antibody response after a single dose of BBV152 vaccine negatively correlates with pre-existing antibodies and induces a significant but low levels of neutralizing antibodies to Omicron variant. medRxiv. 2022:2022.07.22270612.
- 895

896 SUPPLEMENTARY INFORMATION

Supplementary methods and Supplementary figure legends have been provided as a
 separate file.

899

900 FIGURE LEGENDS

Figure 1: Growth curve analysis of B6, B.1.617.1, and B.1.617.2 variants in Calu-3

cells. Calu-3 cells were infected with 0.01 MOI of SARS-CoV-2 virus B.6, B.1.617.1 902 (Kappa), and B.1.617.2 (Delta) variants. (A) Virus titer in the culture supernatant 903 collected at indicated time-points were estimated by plaque assay. Error bars represent 904 geometric mean with 95% CI. (B) Sub-genomic RNA of N gene was estimated by gRT-905 906 PCR. RNAse P was used as internal control for normalization. Error bars represent geometric mean with 95% CI. (C) Calu-3 cells grown on transwell inserts were infected 907 with above variants at 0.3 MOI and TEER was monitored at indicated time points. 908 Values (Mean ± SD) are represented as relative to time zero before infection and 909 910 statistical significance was determined by comparing the zero hour and 48 h readings 911 by two-way ANOVA with Dunnett's multiple comparisons test. (D) Viral titers were measured in supernatants at 48 h pi by focus-forming units. Data are from two or three 912 independent experiments (Mean ± SD). ns: non-significant; ** P<0.01; **** P<0.0001. 913

914

Figure 2: Kappa and Delta variants of SARS-CoV-2 disrupt epithelial junctions. Calu-3 cells were grown on transwell inserts and infected with indicated variants of SARS-CoV-2 at 0.3 MOI. At 48 h pi, cells were fixed and stained with occludin and β catenin antibodies. Nucleocapsid antibody was used to visualize the SARS-CoV-2 infection. Appropriate Alexa Fluor dye-conjugated secondary antibodies were used for

visualization. Nuclei were stained with DAPI. Images were captured at 100X
 magnification. Images were analyzed using cellSens software and Z-projection at
 maximum intensity images are shown in the figure. Scale bar is 10 µM.

923

Figure 3: Growth kinetics of B6, B.1.617.2, and B.1.1.529 variants in Calu-3 cells. 924 (A) Calu-3 cells were infected with above variants of SARS-CoV-2 at 0.3 MOI. Cells 925 were collected at indicated time points and total RNA was isolated to estimate N gene 926 copy numbers by RT-qPCR. RNase P was used as a housekeeping control for 927 normalization. Error bars represent geometric mean with 95% CI. (B) Viral titers were 928 measured in supernatants by plague assay. Error bars represent geometric mean with 929 95% CI. Statistical significance was estimated by two-way ANOVA with Dunnett's 930 931 multiple comparisons test. (C) Western blot analysis of cell lysates prepared from 932 infected cells at indicated time points to detect the expression of SARS-CoV-2 nucleocapsid. GAPDH was used as a loading control. Numbers on the left indicate the 933 934 size of the bands in molecular weight marker. (D) Calu-3 cells were infected at 5 MOI and the amount of internalized RNA was estimated by RT-qPCR as described above. 935 Data are from two independent experiments. Error bars represent geometric mean with 936 95% CI. Statistical significance was estimated by Kruskal-Wallis test with Dunn's 937 multiple comparison test. ns: non-significant, * P<0.05, ** P<0.01, *** P<0.001, **** 938 P<0.0001. 939

940

Figure 4: Antiviral response with B.6, B.1.617.2, and B.1.1.529 variants. Calu-3 cells were infected with indicated variants of SARS-CoV-2 at 0.3 MOI. Cells were

collected at indicated time-points and total RNA was isolated. RT-qPCR was set up to determine the expression of (A) *IFN-β*. (b) *IFN-λ1*, (C) *ISG-15*, and (D) *OAS1*. *GAPDH* was used as house-keeping control for normalization. Data are from two independent experiments (Mean \pm SD). Statistical significance was estimated by two-way ANOVA with Tukey's multiple comparisons test. ns: non-significant, * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001.

949

950 Figure 5: Omicron variant has milder effect on epithelial junctions. Calu-3 cells were grown on transwell inserts under air-liquid interface (ALI) conditions. Cells were 951 952 infected with Delta and Omicron variants at 0.3 MOI. (A) Graph indicates TEER values 953 relative to mock infection after infection at indicated time points from two independent 954 experiments. (Mean and error with range). Statistical significance was estimated by twoway ANOVA with Tukey's multiple comparisons test. (B) Viral titers were measured in 955 supernatants by focus-forming units. Error bars represent (Mean \pm SD) (C) At 36 h pi, 956 cells were fixed and stained with occludin, β-catenin and SARS-CoV-2 nucleocapsid 957 antibody followed by Alexa Fluor dye-conjugated secondary antibodies for visualization. 958 Nuclei were stained with DAPI. Images were captured at 100X magnification. Images 959 960 were analyzed using cellSens software and Z-projection images with maximum intensity are shown in the figure. Scale bar is 10 µM. ns: non-significant, **** P<0.0001. 961

962

Figure 6: Omicron infection induces cross-protective antibodies: Calu-3 cells were
infected with BA.1 and BA.2 sub-lineages of the Omicron variant at 0.3 MOI. Cells were
collected at indicated time points and RNA was isolated. (A) SARS-CoV-2 N sub-

966 genomic copy numbers were estimated using RT-gPCR. RNase P was used as a housekeeping control. (B) Viral titers were measured in supernatants by plague assay. 967 Error bars represent geometric mean value with 95% CI (C) Binding antibodies to 968 969 nucleocapsid (N) and (D) RBD were estimated by guantitative ELISA for the three timepoints post-vaccination as indicated (n=15). (E) Neutralizing antibody titers to Delta 970 variant and (F) Omicron variant was determined in the same samples by FRNT assay. 971 (G) Neutralizing antibody titers to the BA.1 and BA.2 sub-lineages were determined in 972 973 samples from participants that were RT-PCR positive during the ongoing Omicroninduced surge in COVID-19 cases (n=19). Statistical significance was estimated by 974 Kruskal-Wallis test with Dunn's multiple comparison test. ns: not significant. * P<0.05, 975 **** P<0.0001. 976

977

Figure 7: Iron and copper salts significantly inhibits SARS-CoV-2 infection. (A) 978 SARS-CoV-2 RdRp activity assay was performed in the presence of indicated 979 980 concentrations of CaCl₂/CuCl₂/FeSO₄/ZnSO₄ in the standard reaction mix containing MgCl₂ and MnCl₂ and the RdRp complex (nsp7-nsp8-nsp12) of SARS-CoV-2. (B) RdRp 981 assays were performed in the presence of varying of concentrations of ZnSO₄ or (C) 982 FeSO₄ to determine the IC₅₀ values. To determine the effect of metal ions in infection, 983 Calu-3 cells were infected with indicated variants at 0.3 MOI and media containing 50 984 985 µM each of the indicated salts were added after virus adsorption. At 24 h pi, supernatants were collected and viral titers were measured by plaque assay. The graph 986 indicates the virus titers of (D) Delta and (E) Omicron variants. Data are from two or 987 988 three independent experiments. Error bars represent geometric mean with 95% CI.

989 Statistical significance was estimated by Kruskal-Wallis test with Dunn's multiple 990 comparison test. ns: non-significant, * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001.



Figure 2



Figure 3









Figure 6



